产品
编 号：F606833
分子式：C17H26N2O4S
分子量：354.46
分子式：C17H26N2O4S
分子量：354.46
产品类型
规格
价格
是否有货
结构图
CAS No: 53583-79-2
产品详情
生物活性：
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.
体内研究：
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats (p<0.05). In the nucleus accumbens, DOPAC levels are higher in the Sultopride-treated rats than sulpiride treated rats (p<0.05). In the Sultopride-treated rats, DOPAC and HVA levels are higher in the striatum or in the nucleus accumbens than in the medial prefrontal cortex (p<0.05).
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.
体内研究：
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats (p<0.05). In the nucleus accumbens, DOPAC levels are higher in the Sultopride-treated rats than sulpiride treated rats (p<0.05). In the Sultopride-treated rats, DOPAC and HVA levels are higher in the striatum or in the nucleus accumbens than in the medial prefrontal cortex (p<0.05).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备